Developer docs
API playgroundTry for free, no card

Search company profiles

Cureline

Full company profile

uuid0007o8f

Namestring
Cureline
Legal namestring
Cureline, Inc.
Websiteurl
cureline.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Cureline is a translational human biospecimen biobank and contract research organization founded in 2003 and headquartered in South San Francisco. The company procures, processes, and supplies annotated human tissue and biofluid specimens — drawn from a network of 150+ clinical partners across 20 countries — to pharmaceutical, biotechnology, diagnostics, academic, and government clients. It maintains a biorepository of 50,000-100,000 specimens, supports custom collections through IRB-approved protocols, and offers downstream analytical services including the Tissue 2 Target workflow, AQIX-based ex vivo tissue viability, and a Caltech-licensed glycoproteomics capability. The company has completed 4,000+ projects for 700+ clients, including most of the top-20 global pharmaceutical firms.

The business model is project-based: clients contract Cureline to source specific specimen cohorts matched to therapeutic-area, disease-stage, and demographic criteria, with pricing tied to specimen type, annotation depth, processing requirements, and any add-on assay work. Cureline extends its offering upstream via the Palleos Healthcare partnership (clinical study design and execution) and downstream via Cellecta collaboration (customized assay pipelines), positioning itself as a one-stop translational services provider rather than a commodity biobank. The company holds a layered compliance stack — CAP accreditation, HIPAA, WOSB, ANAB, ISO 9001, and ISBER Best Practices adoption — that pre-qualifies it for pharma vendor onboarding.

In January 2026, Cureline was acquired by ABS Bio, a private-equity-backed (3 Boomerang Capital) biospecimen and translational CRO platform, providing capital and consolidation runway for further geographic, therapeutic-area, and service-line expansion.

Short descriptiontext

Cureline is a translational human biospecimen biobank and CRO founded in 2003, sourcing annotated tissue and biofluid specimens from 150+ clinical partners across 20 countries for 700+ pharmaceutical, biotech, diagnostics, academic, and government clients.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Castle, United States
HQ citystring
New Castle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

No data
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biospecimen Procurement and Sales
TypeOne Time License
Description

Sale of human biospecimens including tumor tissues, normal tissues, FFPE blocks, frozen tissues, blood products, bone marrow, and primary cells. Customers order through the company's e-commerce platform or via direct project engagement. Pricing is quote-based based on specimen type, rarity, and collection requirements.

cureline.com
2Laboratory Services
TypeProfessional Services
Description

Fee-for-service laboratory operations including translational histopathology (Cureline BioPathology), molecular testing (Cureline Molecular Services), digital pathology, IHC services, tissue microarray production, and biomarker analysis. Services billed per project or per test.

cureline.com
3Biobanking Consulting and Management
TypeProfessional Services
Description

Consultancy services for biospecimen management including protocol review, site auditing, gap analysis, training, improvement and standardization, ongoing monitoring, and HBS management. Billed as project consulting engagements.

cureline.com
4Custom Protocol Development
TypeProfessional Services
Description

Custom biospecimen collection protocols developed for specific client research programs. Services include study design, inclusion/exclusion criteria development, clinical data collection specifications, and logistics planning.

cureline.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Pricing details3 tiers
1Biospecimen Products (Standard Catalog)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Unit-based pricing for individual specimens (e.g., individual tissue samples, blood products). Prices vary by specimen type, format (FFPE, frozen, etc.), and donor characteristics. Online catalog shows products available to logged-in users only.

order.cureline.com
2Custom Collection Protocols
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based pricing for custom biospecimen collection protocols. Pricing determined by study complexity, number of cases, collection specifications, clinical data requirements, and logistics. Quote-based after feasibility assessment.

cureline.com
3Laboratory Services
ModelOtherBilling cadencePay-as-you-go
Notes

Fee-for-service laboratory work including histology, IHC, molecular testing, digital pathology. Pricing per service or per project depending on scope and volume.

cureline.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Tissue 2 Target
Description

Joint service offering with Cellecta providing validated human samples and expert molecular analysis for drug and biomarker discovery

cureline.com
+2 more records
Core offering1 text field

No source material was provided in the input block; core offering cannot be extracted without supporting sources.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 4,000 projects successfully implemented since 2003
+3 more records
Product overview1 text field

Cureline operates as a global translational and precision medicine Contract Research Organization (CRO) offering an integrated portfolio of human biospecimen (HBS) banking and laboratory services. The core offering centers on the Cureline Tissue Bank, a commercial HBS biobank with a 50,000-100,000 specimen repository in the San Francisco Bay Area, complemented by two specialized subsidiaries: Cureline BioPathology for precision histopathology and translational services (IHC, TMA, digital pathology), and Cureline Molecular Services (CMS) for molecular and cell biology analytics (RNA/DNA/protein work, 3D culture, biomarker discovery). The group also includes BioCrypton for glycoproteomics services. Service offerings span biospecimen procurement across therapeutic areas (oncology, hematology, inflammation, neurology, infectious diseases), various tissue formats (FFPE, fresh frozen, fresh), biofluids (blood, bone marrow, serum, plasma), and primary cells including hepatocytes. Supporting services include custom protocol development, clinical trial sample management, digital pathology scanning, and an e-commerce biorepository catalog. The company maintains clinical networks across 20 countries and was acquired by ABS Bio in January 2026.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

ABS Bio, Inc. acquired Cureline, Inc. to strengthen biopharma drug discovery support. The combined entity has nearly 300 clinical collection sites worldwide, enabling broader and faster service delivery to drug discovery and diagnostics clients. ABS Bio was acquired by 3 Boomerang Capital in 2024. Terms undisclosed.

2Palleos Healthcare
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-05-31
Description

Strategic partnership announced May 31, 2023 to combine preclinical and clinical services, offering end-to-end solutions for medical innovation. Cureline Group and Palleos Healthcare partnership enables comprehensive service offering from preclinical through clinical development.

cureline.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-11-10
Description

Partnership to launch Tissue 2 Target™ Services combining Cureline's biospecimen procurement with Cellecta's biomarker discovery and development capabilities. Joint service offering for preclinical R&D, translational research, and early-stage clinical trials.

Strategic tierKeyTypeTechnology or Integration
Description

Strategic partner providing AQIX RS-I® technology for preservation and transportation of fresh human tissues. AQIX solutions enable up to 72 hours of storage/transport time for human biopsied tissues, maintaining cell viability and morphology. Valuable for international deliveries.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Expertise in large 100-400 cell line panel screening. Performs dose response analysis (IC/GI values), links activity profiles with cell mutation status, and compares candidate drug profiles to thousands of known anticancer agents. Offers complementary tests including combination studies (500+ pairs), drug tolerance detection, and cell cycle analysis.

Strategic tierKeyTypeTechnology or Integration
Description

Provides access to human and animal liver cells and cell medium solutions for in vitro experiments. Enables USA-based companies to access Cytes' products through Cureline's distribution network.

Strategic tierSupportingTypeTechnology or Integration
Description

Provides Cell-Free DNA BCT® blood collection tubes with formaldehyde-free preservative that stabilizes white blood cells. Samples collected are stable for up to 14 days at room temperature. Also provides Cell-Free DNA Urine Preserve for cfDNA stabilization.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Local blood donation center providing access to thousands of pre-qualified donors for procurement of fresh blood specimens from healthy donors and patients with clinical symptoms.

9U.S. Commercial Service
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Department of Commerce service offering trade counseling, market intelligence, business matchmaking, and commercial diplomacy for American companies planning to expand to international markets.

cureline.com
10Biorepositories and Biospecimen Research Branch (BBRB)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Branch of NCI, NIH providing leadership, tools, resources, and policies in biobanking for the global biomedical research community. Cureline participates in BBRB initiatives for biorepository standards and Biospecimen Science studies.

cureline.com
11International Society for Biological and Environmental Repositories (ISBER)
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Long-term member of ISBER since 2008. Dr. Olga Potapova works closely with ISBER administration on development of Best Practices for HBS Biobanking. Cureline actively participates in biobanking community development and harmonization of approaches.

cureline.com
Strategic tierKeyTypeChannel Partner/ Reseller/ Distributor
Description

World's largest AI-powered marketplace for medical research. Cureline listed on platform enabling researchers to discover and procure biospecimen services.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Science Exchange mission is to make scientific discoveries available to every organization. Cureline helps scientists discover medicines in less time and at lower cost through the platform.

Strategic tierSupportingTypeTechnology or Integration
Description

Provider of Panoramic MIDI II slide scanner used for Cureline's digital pathology services. High-definition scanning equipment enabling brightfield or fluorescence scanning at 20X or 40X magnification.

Strategic tierKeyTypeTechnology or Integration
Description

Licensor of unique glycosylation detection technology through BioCrypton, Inc. for investigation of novel biomarkers. Enables Cureline Group to provide proprietary glycoproteomics services.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioIVT is one of the largest global suppliers of human biospecimens and cell-based products to pharma, biotech, and diagnostics companies — directly comparable to Cureline's core biospecimen procurement and biorepository business.

TypeDirect peer
Description

Discovery Life Sciences is a biospecimen and cell services provider offering sample procurement, biospecimen processing, and molecular services across oncology, immunology, and neurology — closely matching Cureline's integrated HBS-to-assay offering.

TypeDirect peer
Description

iSpecimen operates a marketplace connecting researchers with biospecimen suppliers worldwide, with a strong emphasis on annotated human samples — directly comparable to Cureline's marketplace-channel strategy on Scientist.com and Science Exchange.

TypeDirect peer
Description

Indivumed is a biospecimen CRO focused on oncology tissue collection under highly standardized pre-analytical protocols, serving pharma R&D and biomarker discovery — overlapping significantly with Cureline's solid-tumor and CPTAC-style offerings.

5Tissue Solutions (a BioIVT company)
TypeDirect peer
Description

Tissue Solutions procures ethically sourced human tissue for pharma and academic research across multiple therapeutic areas, and is now part of BioIVT — directly comparable to Cureline's tissue procurement and custom protocol development services.

TypeBroad incumbent
Description

Azenta operates automated biorepositories, sample management software, and genomics services for pharma and academic customers — broader in scope than Cureline but directly competitive in biospecimen storage and sample lifecycle management.

TypeBroad incumbent
Description

Labcorp's Central Labs and biospecimen operations provide integrated biorepository and molecular services to global pharma clients — a much larger incumbent that competes with Cureline for enterprise biospecimen and central lab mandates.

TypeOthers
Description

World's largest AI-powered marketplace for medical research services and a current channel partner for Cureline; included as an ecosystem peer given its role in distributing biospecimen and lab services to researchers.

TypeEmerging player
Description

Stemcell Technologies supplies primary cells, cell culture media, and supporting reagents used in pharma R&D — overlapping with Cureline's primary cell and hepatocyte offerings but focused more on research tools than clinical procurement.

TypeOthers
Description

Cytes supplies primary human and animal hepatocytes and cell media; Cureline distributes Cytes products in the U.S. and provides co-located hepatocyte offerings, making it both a partner and a partial peer in the liver-cell niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers21 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cureline

Cureline is a translational human biospecimen biobank and CRO founded in 2003, sourcing annotated tissue and biofluid specimens from 150+ clinical partners across 20 countries for 700+ pharmaceutical, biotech, diagnostics, academic, and government clients.

What Cureline does

Cureline is a translational human biospecimen biobank and contract research organization founded in 2003 and headquartered in South San Francisco. The company procures, processes, and supplies annotated human tissue and biofluid specimens — drawn from a network of 150+ clinical partners across 20 countries — to pharmaceutical, biotechnology, diagnostics, academic, and government clients. It maintains a biorepository of 50,000-100,000 specimens, supports custom collections through IRB-approved protocols, and offers downstream analytical services including the Tissue 2 Target workflow, AQIX-based ex vivo tissue viability, and a Caltech-licensed glycoproteomics capability. The company has completed 4,000+ projects for 700+ clients, including most of the top-20 global pharmaceutical firms.

The business model is project-based: clients contract Cureline to source specific specimen cohorts matched to therapeutic-area, disease-stage, and demographic criteria, with pricing tied to specimen type, annotation depth, processing requirements, and any add-on assay work. Cureline extends its offering upstream via the Palleos Healthcare partnership (clinical study design and execution) and downstream via Cellecta collaboration (customized assay pipelines), positioning itself as a one-stop translational services provider rather than a commodity biobank. The company holds a layered compliance stack — CAP accreditation, HIPAA, WOSB, ANAB, ISO 9001, and ISBER Best Practices adoption — that pre-qualifies it for pharma vendor onboarding.

In January 2026, Cureline was acquired by ABS Bio, a private-equity-backed (3 Boomerang Capital) biospecimen and translational CRO platform, providing capital and consolidation runway for further geographic, therapeutic-area, and service-line expansion.

Cureline firmographics

Firmographics
Name
Cureline
Legal name
Cureline, Inc.
Website
https://cureline.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cureline is a translational human biospecimen biobank and CRO founded in 2003, sourcing annotated tissue and biofluid specimens from 150+ clinical partners across 20 countries for 700+ pharmaceutical, biotech, diagnostics, academic, and government clients.
Ownership category
akta.pro rank

Where Cureline is headquartered

Location

Headquarters

HQ city
New Castle
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Cureline business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. Biospecimen Procurement and Sales: Sale of human biospecimens including tumor tissues, normal tissues, FFPE blocks, frozen tissues, blood products, bone marrow, and primary cells. Customers order through the company's e-commerce platform or via direct project engagement. Pricing is quote-based based on specimen type, rarity, and collection requirements.
  2. Laboratory Services: Fee-for-service laboratory operations including translational histopathology (Cureline BioPathology), molecular testing (Cureline Molecular Services), digital pathology, IHC services, tissue microarray production, and biomarker analysis. Services billed per project or per test.
  3. Biobanking Consulting and Management: Consultancy services for biospecimen management including protocol review, site auditing, gap analysis, training, improvement and standardization, ongoing monitoring, and HBS management. Billed as project consulting engagements.
  4. Custom Protocol Development: Custom biospecimen collection protocols developed for specific client research programs. Services include study design, inclusion/exclusion criteria development, clinical data collection specifications, and logistics planning.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBiospecimen Products (Standard Catalog)
OtherMulti-year contractCustom Collection Protocols
OtherPay-as-you-goLaboratory Services

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Cureline product offering

Product offering

Core offering

No source material was provided in the input block; core offering cannot be extracted without supporting sources.

Product overview

Cureline operates as a global translational and precision medicine Contract Research Organization (CRO) offering an integrated portfolio of human biospecimen (HBS) banking and laboratory services. The core offering centers on the Cureline Tissue Bank, a commercial HBS biobank with a 50,000-100,000 specimen repository in the San Francisco Bay Area, complemented by two specialized subsidiaries: Cureline BioPathology for precision histopathology and translational services (IHC, TMA, digital pathology), and Cureline Molecular Services (CMS) for molecular and cell biology analytics (RNA/DNA/protein work, 3D culture, biomarker discovery). The group also includes BioCrypton for glycoproteomics services. Service offerings span biospecimen procurement across therapeutic areas (oncology, hematology, inflammation, neurology, infectious diseases), various tissue formats (FFPE, fresh frozen, fresh), biofluids (blood, bone marrow, serum, plasma), and primary cells including hepatocytes. Supporting services include custom protocol development, clinical trial sample management, digital pathology scanning, and an e-commerce biorepository catalog. The company maintains clinical networks across 20 countries and was acquired by ABS Bio in January 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Tissue 2 Target: Joint service offering with Cellecta providing validated human samples and expert molecular analysis for drug and biomarker discovery
  • Cancer QUADRUPLET Tissue Set
  • HBS Biorepository

Quantifiable outcome

  • Over 4,000 projects successfully implemented since 2003
  • +3 more outcomes

Companies that use Cureline

Customer profile

Named customers21 records

Segments5 records

Cureline technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Cureline partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, strategic, key and supporting.

  • ABS Bio, Inc.coreStrategic or Co-development Partner · 6 January 2026ABS Bio, Inc. acquired Cureline, Inc. to strengthen biopharma drug discovery support. The combined entity has nearly 300 clinical collection sites worldwide, enabling broader and faster service delivery to drug discovery and diagnostics clients. ABS Bio was acquired by 3 Boomerang Capital in 2024. Terms undisclosed.
  • Palleos HealthcarestrategicStrategic or Co-development Partner · 31 May 2023Strategic partnership announced May 31, 2023 to combine preclinical and clinical services, offering end-to-end solutions for medical innovation. Cureline Group and Palleos Healthcare partnership enables comprehensive service offering from preclinical through clinical development.
  • Cellecta, Inc.strategicStrategic or Co-development Partner · 10 November 2022Partnership to launch Tissue 2 Target™ Services combining Cureline's biospecimen procurement with Cellecta's biomarker discovery and development capabilities. Joint service offering for preclinical R&D, translational research, and early-stage clinical trials.
  • Aqix Ltd.keyTechnology or IntegrationStrategic partner providing AQIX RS-I® technology for preservation and transportation of fresh human tissues. AQIX solutions enable up to 72 hours of storage/transport time for human biopsied tissues, maintaining cell viability and morphology. Valuable for international deliveries.
  • OncoleadkeyStrategic or Co-development PartnerExpertise in large 100-400 cell line panel screening. Performs dose response analysis (IC/GI values), links activity profiles with cell mutation status, and compares candidate drug profiles to thousands of known anticancer agents. Offers complementary tests including combination studies (500+ pairs), drug tolerance detection, and cell cycle analysis.
  • Cytes BiotechnologieskeyTechnology or IntegrationProvides access to human and animal liver cells and cell medium solutions for in vitro experiments. Enables USA-based companies to access Cytes' products through Cureline's distribution network.
  • StrecksupportingTechnology or IntegrationProvides Cell-Free DNA BCT® blood collection tubes with formaldehyde-free preservative that stabilizes white blood cells. Samples collected are stable for up to 14 days at room temperature. Also provides Cell-Free DNA Urine Preserve for cfDNA stabilization.
  • Stanford Blood CentersupportingChannel Partner/ Reseller/ DistributorLocal blood donation center providing access to thousands of pre-qualified donors for procurement of fresh blood specimens from healthy donors and patients with clinical symptoms.
  • U.S. Commercial ServicesupportingGTM or Marketing PartnerDepartment of Commerce service offering trade counseling, market intelligence, business matchmaking, and commercial diplomacy for American companies planning to expand to international markets.
  • Biorepositories and Biospecimen Research Branch (BBRB)strategicStrategic or Co-development PartnerBranch of NCI, NIH providing leadership, tools, resources, and policies in biobanking for the global biomedical research community. Cureline participates in BBRB initiatives for biorepository standards and Biospecimen Science studies.
  • International Society for Biological and Environmental Repositories (ISBER)keyStrategic or Co-development PartnerLong-term member of ISBER since 2008. Dr. Olga Potapova works closely with ISBER administration on development of Best Practices for HBS Biobanking. Cureline actively participates in biobanking community development and harmonization of approaches.
  • Scientist.comkeyChannel Partner/ Reseller/ DistributorWorld's largest AI-powered marketplace for medical research. Cureline listed on platform enabling researchers to discover and procure biospecimen services.
  • Science ExchangesupportingChannel Partner/ Reseller/ DistributorScience Exchange mission is to make scientific discoveries available to every organization. Cureline helps scientists discover medicines in less time and at lower cost through the platform.
  • 3DHISTECHsupportingTechnology or IntegrationProvider of Panoramic MIDI II slide scanner used for Cureline's digital pathology services. High-definition scanning equipment enabling brightfield or fluorescence scanning at 20X or 40X magnification.
  • Caltech (California Institute of Technology)keyTechnology or IntegrationLicensor of unique glycosylation detection technology through BioCrypton, Inc. for investigation of novel biomarkers. Enables Cureline Group to provide proprietary glycoproteomics services.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Cureline competitors and assessment

Company assessment

Direct peers

  • BioIVT: BioIVT is one of the largest global suppliers of human biospecimens and cell-based products to pharma, biotech, and diagnostics companies — directly comparable to Cureline's core biospecimen procurement and biorepository business.
  • Discovery Life Sciences: Discovery Life Sciences is a biospecimen and cell services provider offering sample procurement, biospecimen processing, and molecular services across oncology, immunology, and neurology — closely matching Cureline's integrated HBS-to-assay offering.
  • iSpecimen: iSpecimen operates a marketplace connecting researchers with biospecimen suppliers worldwide, with a strong emphasis on annotated human samples — directly comparable to Cureline's marketplace-channel strategy on Scientist.com and Science Exchange.
  • Indivumed: Indivumed is a biospecimen CRO focused on oncology tissue collection under highly standardized pre-analytical protocols, serving pharma R&D and biomarker discovery — overlapping significantly with Cureline's solid-tumor and CPTAC-style offerings.
  • Tissue Solutions (a BioIVT company): Tissue Solutions procures ethically sourced human tissue for pharma and academic research across multiple therapeutic areas, and is now part of BioIVT — directly comparable to Cureline's tissue procurement and custom protocol development services.

Broad incumbents

  • Azenta Life Sciences (formerly Brooks Life Sciences): Azenta operates automated biorepositories, sample management software, and genomics services for pharma and academic customers — broader in scope than Cureline but directly competitive in biospecimen storage and sample lifecycle management.
  • Labcorp Drug Development: Labcorp's Central Labs and biospecimen operations provide integrated biorepository and molecular services to global pharma clients — a much larger incumbent that competes with Cureline for enterprise biospecimen and central lab mandates.

Others

  • Scientist.com: World's largest AI-powered marketplace for medical research services and a current channel partner for Cureline; included as an ecosystem peer given its role in distributing biospecimen and lab services to researchers.
  • Cytes Biotechnologies: Cytes supplies primary human and animal hepatocytes and cell media; Cureline distributes Cytes products in the U.S. and provides co-located hepatocyte offerings, making it both a partner and a partial peer in the liver-cell niche.

Emerging players

  • Stemcell Technologies: Stemcell Technologies supplies primary cells, cell culture media, and supporting reagents used in pharma R&D — overlapping with Cureline's primary cell and hepatocyte offerings but focused more on research tools than clinical procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cureline social profiles

Digital presence

Cureline compliance and trust

Trust signal

Compliance3 records

Cureline financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cureline leadership team

Management profile

Number of profiles

Cureline subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Cureline funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cureline M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cureline

What does Cureline do?

No source material was provided in the input block; core offering cannot be extracted without supporting sources.

Is Cureline a public or private company?

Cureline is a private company. It is classified as unknown and is currently acquired.

When was Cureline founded?

Cureline was founded in 2003. It employs 11 to 50 people.

Where is Cureline based?

Cureline is headquartered in New Castle, United States, in the North America region.

How does Cureline make money?

Four revenue lines are on record. Biospecimen Procurement and Sales are the primary driver. The others are laboratory Services, biobanking Consulting and Management and custom Protocol Development.

Who are Cureline's main competitors?

Direct peers on record are BioIVT, Discovery Life Sciences, iSpecimen, Indivumed and Tissue Solutions (a BioIVT company). Broad incumbents are Azenta Life Sciences (formerly Brooks Life Sciences) and Labcorp Drug Development. Others are Scientist.com and Cytes Biotechnologies. Stemcell Technologies is listed as an emerging player.

Does Cureline have an API?

No public API is recorded for Cureline.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireABS Bio Acquires Cureline, Broadening Access to Biospecimens & Streamlining Execution from End to EndABS Bio has acquired Cureline, a leading provider of biospecimen procurement and histology services for the pharmaceutical and life sciences industries. The transaction marks ABS Bio's first tuck-in acquisition since 3 Boomerang Capital's original investment in June 2024, expanding the company's capabilities, geographic reach, and client base in biospecimen sourcing. Cureline, founded in 2003 and headquartered in South San Francisco, California, will strengthen ABS Bio's position as a premier partner for pharmaceutical and biotech customers navigating complex procurement needs.CurelineABS Bio, Inc. acquires Cureline, Inc. to strengthen support of biopharma drug discoveryABS Bio acquired Cureline, a specimen procurement and histology services provider, to expand its biospecimen offerings. The combined entity will operate nearly 300 clinical collection sites globally. Acquisition terms were not disclosed.AbsbioABS Bio Acquires Cureline to Strengthen Biopharma Drug Discovery SupportABS Bio, Inc. announced the acquisition of Cureline, Inc., a South San Francisco-based provider of specimen procurement and histology services for the biopharma industry. The combined entity will have nearly 300 clinical collection sites worldwide, enabling broader and faster service delivery to drug discovery and diagnostics clients. ABS Bio, which was acquired by 3 Boomerang Capital in 2024, views the deal as a strategic fit that enhances its biospecimen and cell culture service offerings, with terms undisclosed.